Blog

Jan 18, 2025, 14:33

Aleix Prat – Celebrating Progress at the DEFINITIVE Annual Meeting

Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a post on LinkedIn:

“Celebrating Progress at the DEFINITIVE Annual Meeting!

We’ve just concluded 2 days of fruitful discussions at the DEFINITIVE project annual meeting in Barcelona. This exciting, ongoing clinical trial, funded by the European Commission (Project Number: 101136953), is reshaping how we approach early-stage HER2+ breast cancer.

Patients are currently being randomized, marking a critical step toward demonstrating the power of personalized treatment decisions guided by the HER2DX diagnostic assay.

The main goals of the project are:
Enhancing quality of life without compromising survival or outcomes.
Demonstrating the safety and efficiency of HER2DX.
Reducing costs for hospitals and public health systems.

With a consortium of 18 partners across 9 countries, the DEFINITIVE project exemplifies collaboration and innovation at a European scale. Together, we’re driving advancements in personalized medicine to deliver better care and outcomes for individuals with HER2+ breast cancer.

A huge thank you to everyone involved for your dedication and expertise! Let’s keep the momentum going as the trial progresses.”

Aleix Prat - Celebrating Progress at the DEFINITIVE Annual Meeting

Additional information.

Aleix Prat is the Director of the Cancer Institute at the Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona.

He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.